Interstitial lung disease during trimethoprim/sulfamethoxazole administration

Area of Science:

• Pulmonology
• Pharmacology
• Radiology

Background:

• Interstitial lung diseases (ILDs) can have various etiologies.
• Trimethoprim/sulfamethoxazole (TMP/SMX) is a commonly prescribed antibiotic.
• Drug-induced ILD (DI-ILD) is a recognized but often underdiagnosed condition.

Purpose of the Study:

• To investigate the clinical and radiographic characteristics of ILD associated with TMP/SMX administration.
• To differentiate TMP/SMX-induced ILD from other pulmonary conditions.
• To assess the temporal relationship and clinical course of TMP/SMX-induced ILD.

Main Methods:

• Retrospective review of ten patients with diffuse pulmonary disease on prednisolone.
• Analysis of clinical presentation and radiographic findings in patients developing ILD after TMP/SMX initiation.
• Exclusion of infectious etiologies and underlying disease exacerbation through clinical and radiographic assessment.

Main Results:

• Ten patients developed ILDs after TMP/SMX introduction, distinct from infectious disease or underlying condition exacerbation.
• Radiographic and clinical features suggested drug-induced ILD (DI-ILD) rather than infection or disease flare.
• ILDs appeared early after TMP/SMX initiation, consistent with DI-ILD.
• Most cases presented with mild ILD that resolved promptly, even with continued TMP/SMX therapy.

Conclusions:

• TMP/SMX should be considered a potential cause of DI-ILD.
• Early recognition and differentiation from other ILDs are crucial for appropriate management.
• TMP/SMX-induced ILD appears to be often mild and reversible.